Takahiro Kojima1,2, Hiroyuki Nishiyama3,4, Seiichiro Ozono2,5, Shiro Hinotsu2,6, Naoto Keino7, Akito Yamaguchi2,8, Hideki Sakai2,9, Yutaka Enomoto2,10, Shigeo Horie2,11, Kiyohide Fujimoto2,12, Hideyasu Matsuyama2,13, Takehiko Okamura2,14, Yusuke Kanimoto2,15, Mototsugu Oya2,16, Norio Nonomura2,17, Seiji Naito2,8, Hideyuki Akaza2,18. 1. Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan. 2. UroVysion Clinical Evaluation Group, Tokyo, Japan. 3. Department of Urology, University of Tsukuba, Tsukuba, Ibaraki, Japan. nishiuro@md.tsukuba.ac.jp. 4. UroVysion Clinical Evaluation Group, Tokyo, Japan. nishiuro@md.tsukuba.ac.jp. 5. Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan. 6. Center for Innovative Clinical Medicine, Okayama University, Okayama, Japan. 7. Tsukuba Clinical Research and Development Organization (T-CReDO), University of Tsukuba, Tsukuba, Ibaraki, Japan. 8. Division of Urology, Harasanshin Hospital, Fukuoka, Japan. 9. Department of Urology, Nagasaki University, Nagasaki, Japan. 10. Department of Urology, Mitsui Memorial Hospital, Tokyo, Japan. 11. Department of Urology, Juntendo University, Tokyo, Japan. 12. Department of Urology, Nara Medical University, Kashihara, Nara, Japan. 13. Department of Urology, Yamaguchi University, Yamaguchi, Japan. 14. Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan. 15. Department of Urology, Chutoen General Medical Center, Shizuoka, Japan. 16. Department of Urology, Keio University, Tokyo, Japan. 17. Department of Urology, Osaka University, Osaka, Japan. 18. Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Abstract
BACKGROUND: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). METHODS: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. RESULTS: Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2-64.8%) sensitivity and 72.4% (68.3-76.8%). Urine cytology had 4.5% (0.0-10.7%) sensitivity and 99.8% (99.3-100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up. CONCLUSIONS: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.
BACKGROUND: We evaluated the use of UroVysion fluorescence in situ hybridization tests to detect the intravesical recurrence of bladder cancer during follow-up after a transurethral resection of bladder tumor (TURBT). METHODS: In this prospective, blinded, comparative study, 486 patients treated by TURBT within the prior 2 years were registered at 12 centers. Urine cytology and UroVysion tests were performed once or twice at a central testing laboratory. For the patients with no suspicious findings of bladder cancer in the first analysis, the same examination set was repeated 3 months later as the second analysis. Totals of 468 and 399 patients were eligible for the first and second analyses, respectively. We determined the sensitivity and specificity of two consecutive UroVysion tests. RESULTS:Bladder cancers were identified in 44 patients at the first analysis. The UroVysion test had 50.0% (95% CI 35.2-64.8%) sensitivity and 72.4% (68.3-76.8%). Urine cytology had 4.5% (0.0-10.7%) sensitivity and 99.8% (99.3-100.0%) specificity. The concordant rate of the first and second UroVysion test results was 72% (kappa coefficient 0.157). Interestingly, the patients with two consecutive positive UroVysion test results had the highest cancer detection rate (14.8%), which is greater than those of the patients with a positive result in either (7.2%) or neither (1.2%) of the two tests at the 3-month follow-up. CONCLUSIONS: The UroVysion test provided higher sensitivity than urine cytology to detect bladder cancer during post-TURBT follow-up. Two consecutive UroVysion tests might be a better indicator to predict intravesical recurrence.
Authors: Haythem Dimashkieh; Daynna J Wolff; T Michael Smith; Patricia M Houser; Paul J Nietert; Jack Yang Journal: Cancer Cytopathol Date: 2013-06-25 Impact factor: 5.284
Authors: Brian J Yoder; Marek Skacel; Ryan Hedgepeth; Denise Babineau; James C Ulchaker; Louis S Liou; Jennifer A Brainard; Charles V Biscotti; J Stephen Jones; Raymond R Tubbs Journal: Am J Clin Pathol Date: 2007-02 Impact factor: 2.493
Authors: Jennifer Laudadio; Thomas E Keane; Hugh M Reeves; Stephen J Savage; Rana S Hoda; Janice M Lage; Daynna J Wolff Journal: BJU Int Date: 2005-12 Impact factor: 5.588
Authors: Benjamin R Kipp; R Jeffrey Karnes; Shannon M Brankley; Aaron R Harwood; V Shane Pankratz; Thomas J Sebo; Michael M Blute; Michael M Lieber; Horst Zincke; Kevin C Halling Journal: J Urol Date: 2005-02 Impact factor: 7.450
Authors: Mika-P Raitanen; Risto Aine; Erkki Rintala; Jukka Kallio; Pertti Rajala; Harri Juusela; Teuvo L J Tammela Journal: Eur Urol Date: 2002-03 Impact factor: 20.096
Authors: Michael F Sarosdy; Paul Schellhammer; Gary Bokinsky; Paul Kahn; Roberto Chao; Lawrence Yore; Joseph Zadra; Daniel Burzon; Gerald Osher; Julia A Bridge; Steven Anderson; Sonny L Johansson; Michael Lieber; Mark Soloway; Kerry Flom Journal: J Urol Date: 2002-11 Impact factor: 7.450
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396